Nurix Therapeutics: Roche Has Changed The Economics Of The Bull Case (NASDAQ:NRIX)
· seekingalpha.com
Nurix secures a transformative Roche partnership, gaining $700M upfront, 50% U.S. profit share, and 60% Roche-funded global development for bexobrutideg. Learn more about NRIX stock here.
While Nurix Therapeutics, Inc. ( NRIX ) is still a pre-commercial biotech company with significant execution risk, it is no longer dependent on continually issu...